Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction

Autor(es):Mostrar menos -

Klassen, Aline ^[1] ; Faccio, Andrea Tedesco ^[2] ; Costa Picossi, Carolina Raissa ^[2] ; Matos Cruz Derogis, Priscilla Bento ^[3] ; dos Santos Ferreira, Carlos Eduardo ^[3] ; Lopes, Aline Soriano ^[1] ; Sussulini, Alessandra ^[4] ; Santa Cruz, Elisa Castaneda ^[4] ; Bastos, Rafaela Tudela ^[1] ; Fontoura, Stefanie Caroline ^[1] ; Figueiredo Neto, Antonio Martins ^[5] ; Maggi Tavares, Marina Franco ^[2] ; Izar, Maria Cristina ^[6] ; Helfenstein Fonseca, Francisco Antonio ^[6]

Afiliação do(s) autor(es)

^[1] Fed Univ Sao Paulo UNIFESP, Dept Chem, Diadema, SP - Brazil

^[2] Univ Sao Paulo, Ctr Multiplatform Metabol Studies CEMM, Inst Chem, Sao Paulo, SP - Brazil

^[3] Hosp Israelita Albert Einstein, Sao Paulo, SP - Brazil

^[4] Univ Estadual Campinas, Inst Chem, Dept Analyt Chem, Lab Bioanalyt & Integrated Omics LaBIOmics, UNICAM, POB 6154, BR-13083970 Campinas, SP - Brazil

^[5] Univ Sao Paulo, Inst Phys, Sao Paulo, SP - Brazil

^[6] Fed Univ Sao Paulo UNIFESP, Dept Med, Div Cardiol, Rua Loefgren 1350, BR-04040001 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIFIC REPORTS; v. 11, n. 1 AUG 5 2021.
• Citações Web of Science: 1

Resumo

For cardiovascular disease prevention, statins alone or combined with ezetimibe have been recommended to achieve low-density lipoprotein cholesterol targets, but their effects on other lipids are less reported. This study was designed to examine lipid changes in subjects with ST-segment elevation myocardial infarction (STEMI) after two highly effective lipid-lowering therapies. Twenty patients with STEMI were randomized to be treated with rosuvastatin 20 mg QD or simvastatin 40 mg combined with ezetimibe 10 mg QD for 30 days. Fasting blood samples were collected on the first day (D1) and after 30 days (D30). Lipidomic analysis was performed using the Lipidyzer platform. Similar classic lipid profile was obtained in both groups of lipid-lowering therapies. However, differences with the lipidomic analysis were observed between D30 and D1 for most of the analyzed classes. Differences were noted with lipid-lowering therapies for lipids such as FA, LPC, PC, PE, CE, Cer, and SM, notably in patients treated with rosuvastatin. Correlation studies between classic lipid profiles and lipidomic results showed different information. These findings seem relevant, due to the involvement of these lipid classes in crucial mechanisms of atherosclerosis, and may account for residual cardiovascular risk.Randomized clinical trial: ClinicalTrials.gov, NCT02428374, registered on 28/09/2014. (AU)

• Processo FAPESP: 12/51692-7 - Papel da imunidade adaptativa na evolução da cardiopatia isquêmica após infarto agudo do miocárdio
• Beneficiário: Francisco Antonio Helfenstein Fonseca
• Modalidade de apoio: Auxílio à Pesquisa - Temático